Bernie Sanders urges Novo Nordisk and Sanofi to follow Eli Lilly's example: Drop insulin prices
The chair of the senate health committee says “unacceptable corporate greed” is why insulin prices have risen 1,000% since 1996 in letters addressed to CEOs of Novo Nordisk and Sanofi.
by albert rønning-andersson, translated by daniel pedersen
Bernie Sanders has in his capacity as chair of the US senate health committee trained his sights, again, on pharmaceutical companies Novo Nordisk and Sanofi concerning both drugmakers’ insulin prices, reports industry media Endpoints News.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
.jpg)
Eli Lilly to lower insulin prices by 70% in US
For subscribers
.jpg&w=384&q=75)
